Clinical trials: Extended Time Window
Stroke, Ischemic
Randomization of Endovascular Treatment in Acute Ischemic Stroke in the Extended Time Window
A phase III, randomized, multi-center, open label clinical trial that will examine whether endovascular treatment is superior to standard medical therapy alone in patients who suffer a large vessel anterior circulation ischemic…
- Trial name
- RESILIENTExt (NCT04256096)
- Testing
- Thrombectomy
- Where
- 14 sites in Brazil
- Volunteers
- 376 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Ischemic Stroke
Extending the Time Window for Tenecteplase by Effective Reperfusion in Patients with Large Vessel Occlusion
Patients presenting to the emergency department with an acute ischemic stroke due to a large vessel occlusion eligible for thrombectomy and target mismatch on computed tomography perfusion imaging within 24 hours of onset will be…
- Trial name
- ETERNAL-LVO (NCT04454788)
- Testing
- Tenecteplase, Standard Care (which may include intravenous Alteplase)
- Where
- 7 sites in Australia
- Volunteers
- 242 people
- Sponsor
- University of Melbourne
Acute Mild Ischemic Stroke, Basilar Artery Occlusion
Rescue Endovascular Treatment After Neurological Deterioration in Initially Mild Basilar Artery Occlusion in an Extended Time Window
A prospective, multicenter, open-label, blinded-endpoint, randomized controlled trial to evaluate whether best medical management (BMM) combined with endovascular therapy (EVT) improves neurological outcomes compared to BMM alone…
- Conditions
- Acute Mild Ischemic Stroke, Basilar Artery Occlusion, Rescue Endovascular Treatment, Extended Time Window
- Trial name
- RESCUE-BAO (NCT06843356)
- Testing
- Endovascular Treatment
- Where
- 2 sites in China
- Volunteers
- 159 people
- Sponsor
- First Affiliated Hospital of Wannan Medical College
Acute Ischemic Stroke
rhTNK-tPA for Acute Ischemic Stroke Under Simplified Imaging in the Extended Time Window
The PEARL-SIMPLIFIED trial is a multicenter, prospective, randomized controlled, open-label, blinded-endpoint study. It aims to evaluate the efficacy and safety of intravenous tenecteplase (TNK) in patients with acute ischemic…
- Trial name
- SIMPLIFIED (NCT07606807)
- Testing
- Tenecteplase (rhTNK-tPA) (0.25 mg/kg, to maximum of 25mg), Standard medical treatment
- Where
- China
- Volunteers
- 750 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Stroke Ischemic
Tenecteplase in ReperfUsion Therapy for Posterior Circulation Stroke With Extended Time Window: the TRUST Trial
The primary hypothesis being tested in this trial is that ischemic stroke patients in posterior circulation at 4.5 - 24 hours post onset of stroke will have improved clinical outcomes when given intravenous TNK compared to…
- Trial name
- NCT07073469
- Testing
- Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg), Standard medical treatment
- Volunteers
- 330 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Stroke, Ischemic
Edaravone Dexborneol for Treatment of Acute Ischemic Stroke With Endovascular Therapy in Extended Time Windows
To explore the safety and efficacy of edaravone dexborneol for patients of acute ischemic stroke received endovascular therapy in extended time windows.
- Trial name
- EXISTENT (NCT04817527)
- Testing
- Edaravone Dexborneol
- Where
- China
- Volunteers
- 200 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Healthy Subjects
Effect of Exercise With Low Intensity and Longer Duration Versus High Intensity Interval Training
The purpose of the study is to compare exercise at 70% of maximal heart rate were total energy expenditure is twice compared to interval training at 90- 95% of maximal heart rate.
- Trial name
- NCT01443507
- Testing
- endurance exercise of different duration and intensity
- Where
- Norway
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Volda University College
Stroke, Acute Ischemic
Intravenous rhTNK-tPA Before Stroke Thrombectomy in the Extended Time Window
This randomized, double-blind, placebo-controlled phase III clinical trial aims to evaluate the efficacy and safety of intravenous recombinant human tenecteplase (rhTNK-tPA) in acute ischemic stroke patients with large vessel…
- Trial name
- NCT06987305
- Testing
- Intravenous rhTNK-tPA, Endovascular thrombectomy
- Where
- 4 sites in China
- Volunteers
- 820 people
- Sponsor
- Xinqiao Hospital of Chongqing
Acute Ischemic Stroke
Intravenous Thrombolysis With rhTNK-tPA for Acute Non-large Vessel Occlusion in Extended Time Window
This study is designed to evaluate the efficacy of IV rhTNK-tPA between 4.5 to 24 hours from symptom onset in patients presenting with a non-large vessel occlusion ischemic stroke.
- Trial name
- OPTION (NCT05752916)
- Testing
- rhTNK-tPA, Antiplatelet Agents
- Where
- China
- Volunteers
- 570 people
- Sponsor
- Xuanwu Hospital, Beijing
Stroke, Ischemic
EXtending the tIme Window of Thrombolysis by ButyphThalide up to 6 Hours After Onset (EXIT-BT)
To date, the time window of intravenous thrombolysis is limited within 4.5 hours of stroke onset. Although EXTEND study has proved that intravenous thrombolysis can be extended from 4.5 to 9 hours, but the eligible patients must…
- Trial name
- NCT05189509
- Testing
- TNK-Tissue Plasminogen Activator
- Where
- China
- Volunteers
- 100 people
- Sponsor
- General Hospital of Shenyang Military Region
Acute Ischemic Stroke
Extending the Time Window for Intravenous Tenecteplase in Patients With Distal Medium Vessel Occlusions Stroke
To assess the safety and efficacy of beyond time window TNK intravenous thrombolysis for distal Medium Vessel Occlusion (MeVO) related stroke in a prospective randomized clinical trial.
- Trial name
- NCT06559436
- Testing
- Intravenous thrombolysis, Standard medical management
- Where
- China
- Volunteers
- 560 people
- Sponsor
- The First Affiliated Hospital of University of Science and Technology of China
Stroke, Acute Ischemic
EXtending the Time Window for Thrombolysis in Posterior Circulation Stroke Without Early CT Signs
The primary hypothesis being tested in this trial is that ischemic stroke patients in posterior circulation at 4.5 - 24 hours post onset of stroke will have improved clinical outcomes when given intravenous tissue plasminogen…
- Trial name
- NCT05429476
- Testing
- Tissue Plasminogen Activator (Alteplase)
- Where
- 27 sites in China
- Volunteers
- 234 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Acute Ischemic Stroke, Basilar Artery Occlusion
Basilar Artery Occlusion Chinese Endovascular Trial in the Extended Time Window
A prospective, multi-center, randomized, controlled, open-label, blinded-endpoint trial to evaluate the safety and efficacy of endovascular mechanical thrombectomy for acute basilar artery occlusion in the extended time window
- Trial name
- BAOCHE2 (NCT06560203)
- Testing
- Mechanical thrombectomy
- Where
- China
- Volunteers
- 309 people
- Sponsor
- Capital Medical University
Ischemic Stroke, Acute
Tenecteplase Reperfusion Therapy in Acute Ischaemic Cerebrovascular Events-5
The trial is a multicentre, prospective, open-label, blinded endpoint (PROBE), phase 3, randomized controlled design. Patients with acute ischemic stroke due to basilar artery occlusion presenting within 24 hours will be…
- Trial name
- TRACE-5 (NCT06196320)
- Testing
- Tenecteplase, Best Practice (which may include intravenous Alteplase)
- Where
- 59 sites in China
- Volunteers
- 452 people
- Sponsor
- Beijing Tiantan Hospital
Stroke, Acute Ischemic Stroke
Extended Time Window Intravenous Tenecteplase Thrombolysis Registry for Acute Ischemic Stroke
The EXTEND-TNK Registry is a prospective, multicenter, observational cohort study designed to evaluate the effectiveness and safety of intravenous tenecteplase administered beyond 4.5 hours after last known well in patients with…
- Trial name
- EXTEND-TNK (NCT07536165)
- Testing
- Tenecteplase
- Where
- 2 sites in China
- Volunteers
- 3,000 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Stroke, Acute Ischemic
Endovascular Thrombectomy With and Without Intravenous Thrombolysis in Extended Time Window
The primary hypothesis being tested in this trial is that ischemic stroke patients in large vessel occlusion of anterior circulation at 4.5 - 9 hours post onset of stroke will have improved clinical outcomes when given…
- Trial name
- NCT05634382
- Testing
- Intravenous thrombolysis agents, endovascular thrombectomy
- Where
- China
- Volunteers
- 222 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Basilar Artery Occlusion
Extending the Time Window for Tenecteplase by Recanalization of Basilar Artery Occlusion in Posterior Circulation Stroke
Patients presenting to the emergency department with an acute ischemic stroke due to basilar artery occlusion within 24 hours of stroke onset will be assessed to determine their eligibility for randomization into the trial.
- Trial name
- POST-ETERNAL (NCT05105633)
- Testing
- Tenecteplase, Standard Care (which may include intravenous Alteplase)
- Where
- 17 sites in Australia, Brazil and 1 more
- Volunteers
- 688 people
- Sponsor
- University of Melbourne
Infertility
Extending the hCG OPU Interval
Our and others experience suggest that in some cases delaying oocyte pick up (OPU) for more than 39 hours after hCG injection may be of benefit.
- Trial name
- DelOPU (NCT02871154)
- Testing
- Delaying oocyte pick up beyond 39 hours post hCG
- Volunteers
- 20 people
- Sponsor
- The Baruch Padeh Medical Center, Poriya
Acute Ischemic Stroke, Basilar Artery Occlusion
Efficacy and Safety of Endovascular Recanalization for Acute Basilar Artery Occlusion With Extended Time Window (ANGEL-BAO)
The aim of this study is to assess the efficacy and safety of endovascular treatment versus medical management in patients with acute basilar artery occlusion with extended time window of 24-72 hours from onset.
- Trial name
- ANGEL-BAO (NCT06101667)
- Testing
- Best medical management, Endovascular treatment
- Where
- China
- Volunteers
- 224 people
- Sponsor
- Beijing Tiantan Hospital
Acute Ischemic Stroke
Phase III Clinical Trial of rhTNK-tPA in Treating Acute Ischemic Stroke With Extended Time Window.
This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study designed to evaluate the efficacy of recombinant human tissue-type plasminogen activator variant (rhTNK-tPA) (0.25 mg/kg, maximum dose…
- Trial name
- TRACE-LATE (NCT07201688)
- Testing
- rhTNK-tPA
- Where
- China
- Volunteers
- 890 people
- Sponsor
- CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.